40-PUB: Impact of the Initiation of Is-Cgm Soon after Type 1 Diabetes Mellitus Diagnosis in Adults on Glycemic Indices and Fear of Hypoglycemia—Data from RCT

Use of CGMS has become the standard of glucose control in patients with T1DM. It was shown that use of CGM improves TIR and TBR, and QoL. We aimed to assess the impact of soon after diagnosis (within 1-6 months) initiation of is-CGM on glycemic indices and fear of hypoglycemia (FoH) in adults newly diagnosed with T1DM. After 14 days of wearing the blinded sensor, participants were randomly assigned (1:1) to is-CGM (intervention group) or to self-monitoring of blood glucose (SMBG) with glucometers and blinded CGM (control group). The primary outcomes were change in TB70 and FoH assessed in HFS and main secondary outcomes were change in mean glucose, TIR, TAR between baseline and 4 weeks after randomization. Finally, in this RCT, 23 patients aged 25.6±5.1 were analyzed (14 males, 9 females). All participants were on MDI. Main results of the study are shown in Table 1. The study was terminated early due to changes in reimbursement policy in Poland, as during the study groups of patients eligible for reimbursement were significantly expanded and next generation of is-CGMS was introduced on market. However, our study has shown that, in T1DM patients early after diabetes diagnosis, TIR is high and hypoglycemia risk low. In spite small study group, our data suggest that introducing is-CGM decreases mean glucose; additionally, trend to further increase TIR and decrease TAR was seen. Disclosure J. Hohendorff: Research Support; Abbott. Speaker's Bureau; Dexcom, Inc., Ascensia Diabetes Care. M. Wróbel: None. A. Grzelka-Wozniak: Consultant; Novo Nordisk. Other Relationship; Boehringer-Ingelheim, Novo Nordisk, AstraZeneca, Roche Diabetes Care, Sanofi. M. Kania: None. L. Lapinska: None. D. Rokicka: None. I. Kowalska: Advisory Panel; Abbott. Speaker's Bureau; AstraZeneca, Boehringer-Ingelheim, Eli Lilly and Company, Novo Nordisk, Sanofi. Advisory Panel; Ascensia Diabetes Care. Speaker's Bureau; Berlin-Chemie AG. K. Strojek: None. D. Zozulinska-Ziolkiewicz: Advisory Panel; Abbott, BIOTON. Speaker's Bureau; Boehringer-Ingelheim, Eli Lilly and Company, Ascensia Diabetes Care, Novo Nordisk, Medtronic, Sanofi, Servier Laboratories. Advisory Panel; Eli Lilly and Company. M. Malecki: Advisory Panel; Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott, Dexcom, Inc., Boehringer-Ingelheim. Speaker's Bureau; AstraZeneca, Merck & Co., Inc. Advisory Panel; Krka. Speaker's Bureau; Servier Laboratories. Funding Diabetes Poland Grant 2021